Latest news with #PhaseV
Axios
17-05-2025
- Business
- Axios
Exclusive: PhaseV raises $50M Series A to optimize clinical development
PhaseV, a clinical trial and development software startup, raised a $50 million Series A, CEO Raviv Pryluk tells Axios exclusively. Why it matters: Pharma's need for efficient clinical trials has never been more stark amid FDA upheaval. Pryluk declined to disclose PhaseV's valuation. Follow the money: Accel and Insight Partners led, joined by existing investors Viola Ventures, EXOR and LionBird. PhaseV has ambitious development goals and "will probably raise again in two to three years from now — and that Series B will be substantial," Pryluk says, telling Axios its next funding round could broach three digits. Boston-based PhaseV has raised $65 million since being founded in 2023. How it works: PhaseV is developing AI and machine learning algorithms to accelerate clinical trials and drug development. Its platform aims to help with clinical trial site selection and trial design, and it is being further developed to support clinical trial recruitment and operations, and causal disease modeling. PhaseV has 30 global biotech clients and seven large pharma customers, Pryluk says. What they're saying: "We can now support most of the pivotal decisions that pharma companies need to make during clinical development," Pryluk says. "Whether it's finding the right dose, right indication, right patient population or even the design of the trial as well as dealing with massive amounts of data." Friction point: Patient recruitment is becoming increasingly difficult, heightening demand for technology solutions to ease that burden. "PhaseV is coming up from the other side, saying that if we can be even smarter about how we design the study, we can reduce the number of patients you need by 20% or 30% on day one," Accel partner Matt Robinson says. Stunning stat(s): It can take more than 10 years to get a new drug to market — and clinical development has a 90% failure rate on average. The bottom line: "If there's one thing that we've learned, it's that our clients want a vertical solution, not a point solution," Pryluk says.
San Francisco Chronicle
29-04-2025
- Entertainment
- San Francisco Chronicle
‘Thunderbolts*' review: Gritty, grounded adventure of chaotic superlosers revitalizes the MCU
Populated by the schlubs of the superhero world, 'Thunderbolts*' is another step in the right direction for the Marvel Cinematic Universe as it continues extricating itself from the mess of the Multiverse Saga. By bringing the conflict down to street level with questionable heroes and investing sincerely in characters and relationships, the final Phase V movie is one of the MCU's recent highlights. The grubby heroes in question are all anti- heroes with complicated pasts. Yelena Belova (Florence Pugh as Black Widow 's pseudo-sister, another 'Red Room' assassin), Bucky Barnes (Sebastian Stan as the former Winter Soldier), John Walker (Wyatt Russell as a botched attempt at recreating Captain America), Red Guardian (David Harbour as Russia's version of Captain America, Yelena's pseudo-dad), Taskmaster (Olga Kurylenko as the Avengers-mimicking assassin) and Ghost (Hannah John-Kamen as the 'Ant-Man and the Wasp' phasing enigma) were all Marvel antagonists, more or less; events throw them together most reluctantly. The bickering bunch of B-listers initially has to struggle to survive before discovering a serious threat in the form of Valentina Allegra de Fontaine's (Julia Louis-Dreyfus) 'Sentry' project and its sole survivor, Bob (Lewis Pullman). 'Thunderbolts*' makes hay with its heroes' limitations, as they can't easily escape situations that would be a snap (so to speak) for the MCU's more-powerful denizens. Those limitations lead to some of Marvel's best action sequences, in part because the heroes can't fly around, firing undefined, but plot-serving, blasts. Fighting each other makes for entertaining, in-your-face battles. Fighting together makes for some awesome sequences, especially when they face a nemesis way above their pay grade. Unfortunately, fidelity to that spirit leads to an unsatisfying denouement, but at least the film is trying something different. Most of all, it signals a return to humanness that should hearten Marvel fans. Phase V's missteps (i.e., 'Ant-Man and the Wasp: Quantumania,' 'The Marvels,' 'Secret Invasion' and 'Echo') have tarnished the MCU brand more than any competitor could. But down-to-Earth outings such as ' Captain America: Brave New World ' and ' Daredevil: Born Again ' have the biggest film franchise ever back on track. 'Thunderbolts*' is even 'less super' than those, because not only are the characters weaker than some in the Avengers' pantheon, they're all kind of losers. And that's their great charm. One waggish headline in the film calls them the 'B-Vengers.' Directed by Berkeley native Jake Schreier ('Robot and Frank'; ' Beef '), 'Thunderbolts*'s' filmmaking is notably gritty (as in dirt under one's nails), messy and real-feeling. And that's good. Sets can be appropriately chaotic, like Red Guardian's unkempt domicile or a ransacked vault. The costumes can be purely functional or bargain basement, like the stitching on Guardian's uniform that looks like he did it himself; elegant, like Ghost's containment suit; or surprisingly impressive, like the Golden God/Scary Superman look of a fully realized Sentry. Top-flight VFX also help Schreier and Co. set this in a realer world. That approach pays off most of all in the tangled web of psyches deflated by inferiority complexes that inform these, as Elvis Costello might call them, Less Than Heroes. Their inner landscapes feel more tangible, relatable and genuine than most superheroes'. The skilled, versatile Pugh is well-equipped to anchor a popcorn movie with emotional complexity. One of the themes in 'The Falcon and the Winter Soldier' was Bucky's climb back from PTSD after years of killing; Pugh's Yelena has, as Scarlett Johansson's Natasha said, 'a lot of red on her ledger.' Her self-doubt and depression are unusual colors in a comic-movie portrait. Stan is a welcome sight as Bucky. Harbour's Red Guardian earns the most laughs – what his dialect may lack in consistency, he more than makes up for in enthusiasm. Russell is another standout as the dime-store Captain America, memorably (and accurately) called an '—hole' by another character. Louis-Dreyfus elevates anything she's in. And Pullman will turn a lot of heads as the timid guy-turned-scariest MCU baddie since Thanos. The fun and human 'Thunderbolts*' is an encouraging sign for the MCU's future. Fans should make sure to stay until the end of the credits.
Hindustan Times
27-04-2025
- Entertainment
- Hindustan Times
Julia Louis-Dreyfus says Seinfeld's Elaine would have been an MCU villain, opens up on her Thunderbolts role
Marvel Cinematic Universe's Phase V is coming to an end with the upcoming release, Thunderbolts. The film, which continues on from Black Widow and Falcon and the Winter Soldier, is meant to set up the next phase of the MCU. And pivotal to that setup is the character Valentina Allegra de Fontaine, the devious version of Nick Fury. Ahead of the release, Julia Louis-Dreyfus, who plays Val in the MCU, talks about her role and more. (Also read: Thunderbolts first reactions call film 'one of the best Marvel movies in years', leak praises 'amazing' action scenes) Thunderbolts hints that Valentina has replaced not just Nick Fury but also Tony Stark. The new promos show her bossing around in the Avengers Tower (sinisterly nicknamed the Watchtower now). Ask her if she is a combination of the two iconic characters, and Julia responds, "I think you're spot on. That's why it was fun to play her; we haven't seen a character like this in the MCU. She is a complicated, maybe shady, maybe not person. You don't know if she is telling the truth or not. The mystery around her is a delicious area to play in." Julia had first gained fame in the early 90s playing Elaine Benes on Seinfeld. Ask her how the morally ambiguous Elaine would fit in the MCU, and she responds with a laugh, "She would be a bad guy, and then she would not make it past the first story she was in. Somebody would off her and that would be the end." And if Elaine ever crosses Valentina in the story? "Val would crush her like a bug," exclaims Julia. Thunderbolts is MCU's first antihero/villain-led film as it focuses on a team of misfits trying to stop a greater threat. Directed by Jake Schreier, the film stars Florence Pugh, Sebastian Stan, Wyatt Russell, Olga Kurylenko, Lewis Pullman, Geraldine Viswanathan, David Harbour, and Hannah John-Kamen. It is set to release in India on May 1 and globally on May 2.
Yahoo
22-04-2025
- Health
- Yahoo
PhaseV to Host New Webinar Episode on Patient-Centric Clinical Development
BOSTON, April 22, 2025 /PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, today announced that the second episode in its webinar series will focus on improving patient-centricity and efficiency in clinical trial design. The session Putting Patients First: Novelty, Adaptivity, and Collaboration in Clinical Development, will air on Thursday, May 1, 2025, at 1:00 PM EST. Click here to register for the webinar, which will feature industry leaders exploring how patient-centric approaches are shaping adaptive trial design and driving more efficient clinical development: Angela Dobes, Senior Vice President, IBD Plexus, Crohn's & Colitis Foundation Oren Hershkovitz, PhD, CEO, Enlivex Therapeutics Aaron Galluzzi, Consulting Statistician, Alimentiv Moderated by Keren Peri-Hanania, MD, Medical Director at PhaseV, the panel will discuss: How patient-centricity in trial design increases efficiency in clinical development The integration of real-world data with causal and adaptive methods to improve patient stratification and enhance trial results The role of patient advocacy organizations in connecting sponsors, patients, and technology developers to increase the inclusivity and impact of new research The importance of collaboration, providing examples of biotech sponsors, CROs, foundations, and technology providers working together to accelerate drug development while prioritizing patient needs "Our webinar series is more than a discussion, it's an opportunity to share the practical insights we've gained in clinical development to help drive meaningful change in the field," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "Participants will gain actionable strategies to incorporate new AI-driven approaches, real-time data and patient-centered design into their trials for more efficient and effective clinical development." About PhaseV PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions. PhaseV's platform has reduced trial costs by up to 25%, decreased enrollment size and trial duration by up to 40%, and increased the probability of trial success by over 30%. To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others. Learn more at and follow us on LinkedIn. Infographic: Media Contact: Ellie HansonFINN Partners for 929-588-2008 View original content to download multimedia: SOURCE PhaseV Sign in to access your portfolio
